Skip to main content

Journal of Hematology & Oncology: 10 years on

2018 marked the 10 year anniversary since the Journal of Hematology & Oncology published its first article. Over the past decade, the journal has established itself in the top quartile of journals in both its fields worldwide. 

To mark this occasion, we're looking back at the journal's milestone achievements and highlighting some of the best content from the past 10 years.

Click here to enlarge the infographicNew Content Item​​​​​​​

Comments from our community

New Content Item

"Journal of Hematology & Oncology has quickly emerged as one of the significant journals in its fields. With its high editorial standards, its value to the scientific community and Prof. Delong Liu at the helm, I have no doubt that the journal will continue to go from strength to strength in the years to come."
– Dr Srdan Verstovsek, JHO Editorial Board member
MD Anderson Cancer Center, USA

New Content Item"It is a real honor for me to congratulate the Journal of Hematology and Oncology (JHO) for its 10th anniversary. JHO has proven itself during these years as a leading journal in the field of hematology, including stem cell transplantation and cellular therapy, with numerous original articles— many of them practice changers. And I may guess it is only the beginning. Happy anniversary!"
– Prof Arnon Nagler, JHO author
Tel Aviv University, Israel

New Content Item"Over just 10 years, JHO has become one of the journals in the field of hematology/oncology with an impact factor of >6 under the leadership of Prof. Delong Liu. It was a wonderful experience to publish my clinical trial results at JHO. I am confident that JHO will continue to publish high quality papers to make a strong impact in the hematology/oncology fields."
– Dr Hongtao Liu, CAHON member
University of Chicago Medical Center, USA

Editor's highlights: Prof Delong Liu's annual top picks

2017 Clinical trials of CAR-T cells in China
2016 Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
2015 Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
2014 SINE (selective inhibitor of nuclear export) – translational science in a new class of anti-cancer agents
2013 Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group
2012 A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
2011 A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
2010 Dysregulation of miR-15a and miR-214 in human pancreatic cancer
2009 Mechanism of action of lenalidomide in hematological malignancies
2008 Treatment of stage I seminoma: is it time to change your practice?

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 29.5
    5-year Journal Impact Factor: 26.9
    Source Normalized Impact per Paper (SNIP): 4.489
    SCImago Journal Rank (SJR): 7.522

    Speed 2023
    Submission to first editorial decision (median days): 4
    Submission to acceptance (median days): 59

    Usage 2023
    Downloads: 3,173,795
    Altmetric mentions: 2,671

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here